Różycka-Baczyńska Anna M, Stepaniec Igor M, Warzycha Marta, Zdolińska-Malinowska Izabela, Oldak Tomasz, Rozwadowska Natalia, Kolanowski Tomasz J
Research and Development Department, Polski Bank Komórek Macierzystych S.A. (FamiCord Group), Warsaw, Poland.
Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
J Appl Genet. 2024 Dec 2. doi: 10.1007/s13353-024-00917-5.
Mesenchymal stromal cells (MSCs) have a wide range of therapeutic applications due to their multipotency, immunomodulatory, and anti-inflammatory properties. Their ability to migrate and recolonize damaged tissues is also remarkable. However, the controversial occurrence of spontaneous tumorigenesis or malignant transformation of MSCs raises concerns about proposed cell-based therapies for patients that researchers must address. There are several in vitro and in vivo strategies for MSC safety approval, but there is still no described coherent scheme that allows the assessment of MSC oncogenic potential in a simple, robust, and reproducible manner. Here, we have developed a diagnostic panel of molecular markers that allows for the accurate verification of the quality and safety of MSCs. Moreover, presented in this article diagnostic panel that can define the origin and tumorigenicity of MSCs can be easily introduced into the routine quality control processes of MSC-based product manufacturing which will improve further clinical applications of MSCs.
间充质基质细胞（MSCs）因其多能性、免疫调节和抗炎特性而具有广泛的治疗应用。它们迁移并重新定殖于受损组织的能力也很显著。然而，MSCs自发肿瘤发生或恶性转化这一有争议的现象引发了研究人员必须解决的对于针对患者的细胞疗法的担忧。有几种用于MSCs安全性批准的体外和体内策略，但仍然没有一种连贯的方案能够以简单、可靠且可重复的方式评估MSCs的致癌潜力。在此，我们开发了一组分子标志物诊断面板，可用于准确验证MSCs的质量和安全性。此外，本文介绍的能够定义MSCs起源和致瘤性的诊断面板可轻松引入基于MSCs的产品制造的常规质量控制流程，这将进一步改善MSCs的临床应用。
